PP
URGN icon

PDT Partners’s UroGen Pharma URGN Stock Holding History

PDT Partners’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,009
Closed -$156K – 1098
2022
Q2 		$156K Sell
19,009
-1,975
-9% -$13.6K 0.01% 851
2022
Q1 		$183K Buy
+20,984
New +$164K 0.02% 826

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PDT Partners's URGN Position: Q3 2022 in Review

PDT Partners sold out of UroGen Pharma (URGN) in Q3 2022, closing a stake of 19,009 shares — an estimated $156K sold.

PDT Partners first reported a position in URGN in Q1 2022 and held it in 2 quarters. The position peaked at $183K in Q1 2022. 60 funds tracked by Wall St. Rank hold URGN as of Q3 2022.

  • PDT Partners reported no remaining UroGen Pharma position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 19,009 UroGen Pharma shares in Q3 2022, an estimated $156K.
  • PDT Partners first reported a position in UroGen Pharma in Q1 2022 and held it in 2 quarters.
  • PDT Partners's UroGen Pharma position peaked at $183K in Q1 2022.
  • 60 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.